Business model

Identification of nanoparticle targets both novel and standard, and build a pipeline of nanoparticle drug candidates with strong pre-clinical data both in-house development and acquiring IP rights. Thereafter partner to take the products with pharma companies or cancer research institutes to generate clinical data for regulatory approvals through licensing the IP rights or joint development.

What we do

Primarily new target identification, drug design, formulation development, in-vitro cell line studies and pre-clinical data on animals for regulatory filings for clinical trials.


Our strength derived from our unique ability of understanding and integrating best of pharmaceutical knowledge and nanodrug design with the bio-nanotech tools and techniques to address the unmet needs of cancer.


The core competency of the organization comes from our competent and experienced executive team as well as renowned advisory board, who have excellent technology, business, preclinical and clinical research credentials combined with global exposure. The company is promoted and executed by a team of passionate individuals who believe in innovation and development of novel cancer nanotherapeutics to the market.